CEO Martin Olin steps down
Bergen, Norway, 10 October 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical need, announces today that CEO, Martin Olin will be leaving the company to pursue other opportunities. Martin will remain in his position during a transition period.
“On behalf of the Board of Directors, I want to thank him for his work and leadership over the last three years. Martin has since he joined navigated the company through a strategic transition and established a solid platform for the further development of bemcentinib. On behalf of the company, I wish him all the best in his new endeavors”, said Anders Tullgren, Chairman of BerGenBio.
The Board of Directors has initiated a succession process and will actively work with the management to support and review the business requirements.
"I have thoroughly enjoyed my past three years at BerGenBio. It has been a privilege to lead the company and contribute to developing a medicine that can potentially be of great importance to a large number of patients. The company has a very competent team and an exciting time ahead, and I will follow its path and progress closely," said Martin Olin.
Anders Tullgren
Chairman of the Board of Directors
Contact requests through:
or
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
or
Jan Lilleby
jl@lillebyfrisch.no
+47 90 55 16 98
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.